Table 5.
Observed Prevalence, Remission and Incidence of Comorbiditiesa and Modeled Prevalence Estimates by Time Point in Relation to Initial Bariatric Procedure, by Procedure.
| Observed Prevalence, Remission and Incidence of Comorbidities | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| %, No./Totala |
||||||||||||
| Baseline | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |||||||
| Sleeve Gastrectomy | ||||||||||||
| Diabetes | ||||||||||||
| Prevalence | 30.0 | 15/50 | 7.0 | 3/43 | 8.1 | 3/37 | 14.7 | 5/34 | 13.8 | 4/29 | 8.6 | 3/35 |
| Remission | NA | NA | 77.8 | 7/9 | 62.5 | 5/8 | 62.5 | 5/8 | 66.7 | 4/6 | 66.7 | 4/6 |
| Incidence | NA | NA | 0.0 | 0/30 | 0.0 | 0/27 | 4.4 | 1/23 | 9.1 | 2/22 | 3.7 | 1/27 |
| High LDL | ||||||||||||
| Prevalence | 44.9 | 22/49 | 35.7 | 10/28 | 37.5 | 6/16 | 45.0 | 9/20 | 31.6 | 6/19 | 25.0 | 5/20 |
| Remission | NA | NA | 22.2 | 2/9 | 33.3 | 2/6 | 30.0 | 3/10 | 33.3 | 3/9 | 44.4 | 4/9 |
| Incidence | NA | NA | 11.8 | 2/17 | 20.0 | 2/10 | 12.5 | 1/8 | 0.0 | 0/10 | 0.0 | 0/10 |
| High triglycerides | ||||||||||||
| Prevalence | 22.6 | 12/53 | 6.7 | 2/30 | 12.5 | 2/16 | 9.5 | 2/21 | 4.6 | 1/22 | 9.1 | 2/22 |
| Remission | NA | NA | 33.3 | 1/3 | 0.0 | 0/2 | 75.0 | 3/4 | 50.0 | 1/2 | 60.0 | 3/5 |
| Incidence | NA | NA | 0.0 | 0/25 | 0.0 | 0/14 | 0.0 | 0/16 | 0.0 | 0/20 | 0.0 | 0/17 |
| Low HDL | ||||||||||||
| Prevalence | 37.0 | 20/54 | 6.4 | 3/47 | 15.4 | 6/39 | 10.8 | 4/37 | 7.9 | 3/38 | 7.9 | 3/38 |
| Remission | NA | NA | 80.0 | 12/15 | 61.5 | 8/13 | 66.7 | 8/12 | 75.0 | 9/12 | 76.9 | 10/13 |
| Incidence | NA | NA | 0.0 | 0/30 | 3.9 | 1/26 | 0.0 | 0/24 | 0.0 | 0/25 | 0.0 | 0/25 |
| Hypertension | ||||||||||||
| Prevalence | 81.1 | 43/53 | 61.7 | 29/47 | 69.1 | 29/42 | 59.1 | 26/44 | 51.4 | 19/37 | 55.3 | 21/38 |
| Remission | NA | NA | 30.6 | 11/36 | 24.2 | 8/33 | 31.4 | 11/35 | 37.9 | 11/29 | 31.0 | 9/29 |
| Incidence | NA | NA | 14.3 | 1/7 | 42.9 | 3/7 | 0.0 | 0/6 | 16.7 | 1/6 | 14.3 | 1/7 |
| Roux-en-Y Gastric Bypass | ||||||||||||
| Diabetes | ||||||||||||
| Prevalence | 33.3 | 19/57 | 8.6 | 3/35 | 6.5 | 2/31 | 7.1 | 2/28 | 9.4 | 3/32 | 3.2 | 1/31 |
| Remission | NA | NA | 75.0 | 9/12 | 87.5 | 7/8 | 100.0 | 8/8 | 77.8 | 7/9 | 88.9 | 8/9 |
| Incidence | NA | NA | 0.0 | 0/23 | 4.4 | 1/23 | 10.0 | 2/20 | 4.4 | 1/23 | 0.0 | 0/22 |
| High LDL | ||||||||||||
| Prevalence | 40.4 | 21/52 | 16.0 | 4/25 | 13.6 | 3/22 | 13.0 | 3/23 | 14.3 | 3/21 | 16.0 | 4/25 |
| Remission | NA | NA | 69.2 | 9/13 | 66.7 | 6/9 | 80.0 | 8/10 | 75.0 | 6/8 | 63.6 | 7/11 |
| Incidence | NA | NA | 0.0 | 0/11 | 0.0 | 0/12 | 9.1 | 1/11 | 8.3 | 1/12 | 0.0 | 0/13 |
| High triglycerides | ||||||||||||
| Prevalence | 13.5 | 7/52 | 3.7 | 1/27 | 4.0 | 1/25 | 8.3 | 2/24 | 4.6 | 1/22 | 4.0 | 1/25 |
| Remission | NA | NA | 100.0 | 2/2 | 50.0 | 1/2 | 0.0 | 0/2 | 0.0 | 0/1 | 66.7 | 2/3 |
| Incidence | NA | NA | 4.2 | 1/24 | 0.0 | 0/22 | 0.0 | 0/20 | 0.0 | 0/20 | 0.0 | 0/21 |
| Low HDL | ||||||||||||
| Prevalence | 37.5 | 21/56 | 13.2 | 5/38 | 5.7 | 2/35 | 3.3 | 1/30 | 9.4 | 3/32 | 3.2 | 1/31 |
| Remission | NA | NA | 61.5 | 8/13 | 75.0 | 6/8 | 100.0 | 7/7 | 77.8 | 7/9 | 85.7 | 6/7 |
| Incidence | NA | NA | 0.0 | 0/25 | 0.0 | 0/27 | 4.4 | 1/23 | 4.4 | 1/23 | 0.0 | 0/24 |
| Hypertension | ||||||||||||
| Prevalence | 86.0 | 49/57 | 48.9 | 22/45 | 46.0 | 17/37 | 57.6 | 19/33 | 51.4 | 18/35 | 50.0 | 17/34 |
| Remission | NA | NA | 44.7 | 17/38 | 50.0 | 16/32 | 37.9 | 11/29 | 41.9 | 13/31 | 44.8 | 13/29 |
| Incidence | NA | NA | 14.3 | 1/7 | 20.0 | 1/5 | 25.0 | 1/4 | 0.0 | 0/4 | 20.0 | 1/5 |
| Model-Based Estimates, % (95% Confidence Interval) b | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P |
|||||||||||||
| Baseline | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | Year 5 vs. BL |
|||||||
| Sleeve Gastrectomy | |||||||||||||
| Diabetes (n=54) | 31.2 | (18.0–44.4) | 7.7 | (0.1–15.3) | 10.0 | (1.5–18.4) | 15.5 | (5.0–25.9) | 17.0 | (5.7–28.3) | 13.0 | (3.6–22.3) | 0.02 |
| High LDL (n=53) | 44.5 | (30.5–58.6) | 37.7 | (22.2–53.1) | 41.1 | (23.1–59.0) | 38.8 | (22.8–54.8) | 31.6 | (14.6–48.7) | 24.2 | (7.6–40.7) | 0.10 |
| High trig. (n=55) | 23.3 | (11.9–34.8) | 9.4 | (0.9–17.9) | 13.7 | (4.4–23.1) | 10.4 | (0.0–20.8) | 7.1 | (−1.0–15.1) | 7.8 | (−2.8–18.4) | 0.16 |
| Low HDL (n=56) | 36.6 | (23.6–49.7) | 6.4 | (−0.6–13.4) | 14.5 | (4.6–24.5) | 8.9 | (0.4–17.3) | 7.9 | (0.1–15.8) | 9.1 | (0.8–17.4) | <0.01 |
| Hypertension (n=57) | 81.5 | (70.9–92.2) | 61.5 | (47.7–75.3) | 66.0 | (52.5–79.5) | 60.1 | (46.1–74.1) | 60.1 | (45.4–74.9) | 63.7 | (49.5–77.9) | 0.048 |
| Roux-en-Y Gastric Bypass | |||||||||||||
| Diabetes (n=57) | 33.3 | (20.8–45.8) | 9.2 | (0.4–18.0) | 4.4 | (−5.5–14.3) | 4.9 | (−3.8–13.7) | 12.1 | (1.9–22.3) | 2.8 | (−2.7–8.3) | 0.03 |
| High LDL (n=55) | 39.9 | (26.3–53.4) | 15.1 | (3.0–27.2) | 16.9 | (4.6–29.3) | 15.6 | (3.3–28.0) | 14.5 | (1.6–27.4) | 15.5 | (4.3–26.8) | 0.02 |
| High trig. (n=55) | 13.1 | (3.9–22.4) | 3.8 | (−3.5–11.1) | 3.3 | (−2.5–9.2) | 8.7 | (0.7–16.6) | 4.1 | (−1.3–9.6) | 3.5 | (−2.4–9.3) | 0.17 |
| Low HDL (n=56) | 37.5 | (24.5–50.5) | 13.2 | (3.4–23.0) | 5.7 | (−1.6–13.0) | 3.1 | (−3.2–9.3) | 7.6 | (−0.8–16.1) | 3.7 | (−2.3–9.7) | 0.01 |
| Hypertension (n=57) | 86.0 | (76.7–95.2) | 48.3 | (33.9–62.8) | 40.4 | (24.9–55.9) | 55.4 | (39.2–71.5) | 50.9 | (35.2–66.5) | 53.6 | (37.7–69.5) | <0.01 |
Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein; NA, not applicable.
a
There are 57 SG and 57 RYGB participants. Missing data vary for each comorbid condition due to varying data requirements.
b
Estimates are based on mixed models that controlled for baseline age, smoking and site, which were significantly associated with missing follow-up data.